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Whole genome and transcriptome sequencing technologies have led to the identification
of many long non-coding RNAs (lncRNAs) and stimulated the research of their role in
health and disease. LncRNAs participate in the regulation of critical signaling pathways
including cell growth, motility, apoptosis, and differentiation; and their expression
has been found dysregulated in human tumors. Thus, lncRNAs have emerged as
new players in the initiation, maintenance and progression of tumorigenesis. PVT1
(plasmacytoma variant translocation 1) lncRNA is located on chromosomal 8q24.21, a
large locus frequently amplified in human cancers and predictive of increased cancer
risk in genome-wide association studies (GWAS). Combined, colorectal and gastric
adenocarcinomas are the most frequent tumor malignancies and also the leading cause
of cancer-related deaths worldwide. PVT1 expression is elevated in gastrointestinal
tumors and correlates with poor patient prognosis. In this review, we discuss the
mechanisms of action underlying PVT1 oncogenic role in colorectal and gastric cancer
such as MYC upregulation, miRNA production, competitive endogenous RNA (ceRNA)
function, protein stabilization, and epigenetic regulation. We also illustrate the potential
role of PVT1 as prognostic biomarker and its relationship with resistance to current
chemotherapeutic treatments.
Keywords: PVT1, lncRNA, siRNA, ceRNA, Myc, colorectal/gastric cancer
INTRODUCTION
According to the latest data released by the International Agency for Research on Cancer (IARC),
cancer of the digestive tract is the leading cause of cancer and cancer-related death worldwide
(1–3) (Table 1). Digestive tract tumors include malignancies arising in the oral cavity, esophagus,
stomach, small, and large intestines, rectum and anus. Briefly, oral cancer is a subgroup of head and
neck cancers, characterized by the growth of tumor cells in the lining of the lips, mouth, and upper
throat. Oral squamous cell carcinoma represents the most frequent oral neoplasm and arises from
epithelial cells. The greatest risk factor for oral cancer is the tobacco and/or alcohol use. However,
the exposure to chemical carcinogens, ultraviolet/ionizing radiation and viral infections, such as
Human Papilloma virus (HPV), Epstein-Barr Virus (EBV) or Hepatitis C virus (HCV), are also
known to increase oral cancer incidence rate (4). Esophageal cancer occurs when malignant cells
arise in the tissue of the esophagus, the tube that transports the food from themouth to the stomach.
There are two major subtypes of esophageal cancer, which are epidemiologically and biologically
very distinct. Esophageal squamous cell carcinomas occur in the epithelial cells of the mucosa, are
frequently found in the upper and middle sections of the esophagus and associate with risk factors
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TABLE 1 | Incidence and mortality rates of tumor malignancies in the digestive tract worldwide.
Incidence Mortality
Number Ranking Number Ranking
Males Females Both sexes Males Females Both sexes
Colorectal 1,849,518 3 2 3 880,792 4 3 2
Stomach 1,033,701 4 7 5 782,685 3 5 3
Esophagus 572,034 7 13 7 508,585 6 9 6
Lips/oral cavity 354,864 11 19 16 177,384 12 16 15
Total digestive tract 3,810,117 1 (21.1%) 2,349,446 1 (24.6%)
Incidence and mortality numbers for digestive tract malignancies and position occupied in the ranking when compared to other cancers are shown. Percentages considering all tumor
sites are indicated in brackets. Data was extracted from the 2018 Global Cancer Observatory (International Agency for Research on Cancer) (1).
leading to recurrent chemical or physical insults to mucosa,
i.e., tobacco, alcohol, or hot drinks use. Conversely, esophageal
adenocarcinomas arise from the glandular cells in the mucosa,
are more abundant in the lower section of the esophagus, and are
associated with gastro-esophageal reflux and obesity as the main
risk factors (5, 6). In turn, gastric cancer occurs when malignant
cancer cells grow and colonize the wall of the stomach. The most
common form of stomach cancer is the gastric adenocarcinoma,
which originates in the epithelial cells from the mucosa. Other
less common types of stomach cancer include gastro-intestinal
stromal tumors, which develop in the connective tissue from the
stomach wall, squamous cell carcinomas and carcinoid tumors.
Traditionally, gastric adenocarcinomas are divided into two
main histological subtypes, namely intestinal and diffuse. These
subtypes follow very different oncogenic programs and thus
display different molecular profiles (7). The etiology of gastric
cancer is multifactorial but dietary factors, such as high salt
and nitrate intake, and Helicobacter pylori infection increase the
risk of gastric cancer development and progression (8–10). And
finally, colorectal cancer occurs when tumor cells grow in the
colon or rectum inner lining. The normal intestinal epithelium
is maintained by a tight balance of proliferation, migration
and cell death. Tumorigenesis occurs when these mechanisms
become deregulated resulting in cell hyperproliferation and
loss of differentiation, evidenced by the formation of aberrant
crypts evolving into adenomatous polyps and subsequently into
adenocarcinomas. Only a small proportion of colorectal tumors
display a mesenchymal origin. Alcohol consumption, smoking,
high fat diet as well as obesity are well-known risk factors for
colorectal cancer (11).
Among all tumor types in the digestive tract, colorectal, and
gastric cancers exhibit the highest incidence and mortality rates.
Specifically, colorectal cancer is the third most common cancer
type in men after lung and prostate cancer; and the second most
common in women after breast cancer. Stomach cancer, in turn,
ranks fourth and seventh regarding its incidence in men and
women, respectively. Only in 2018, 1.8 million colorectal and
about 1 million stomach cancer cases were diagnosed worldwide,
accounting for almost 900,000 and 800,000 deaths, respectively
(Table 1). Moreover, it is expected that by 2040, the incidence of
colorectal cancer will raise by 30% andmortality by 40%; whereas
statistics for stomach cancer will both worriedly increase by 60%
due to its high prevalence in Asian countries, whose population
and economic growth rates are increasing. The prognosis of
gastrointestinal cancer patients largely depends on tumor stage
at the time of diagnosis (Table 2). Additionally, tumor staging
strongly influences the clinical management (12–15). Thus,
gastrointestinal cancer represents a major health and social
issue requiring great investment from governments worldwide to
cover the cost of prevention, diagnosis and treatment.
Efficient clinical management of cancer largely relies on the
identification and study of key mediators of the tumorigenic
process, both at onset and progression. Classically, most of
the research efforts in tumor biology have been focused on
protein-coding oncogenes, tumor-suppressor genes and DNA
repair genes. But with the irruption of whole-transcriptome
sequencing (RNAseq) technologies and computational sciences,
we have gained great insights into non-coding RNAs (ncRNAs).
These RNAs cover over 90% of the human genome and
regulate a great variety of cellular processes including chromatin
architecture and remodeling, transcription, post-transcriptional
modification, epigenetic regulation, and signal transduction,
both in physiological and pathological processes including cancer
(16–18). An arbitrary 200-nucleotide length cut-off allows the
classification of non-coding transcripts into two categories: short
and long ncRNAs. Short ncRNAs are represented by microRNAs
(miRNAs), PIWI-interacting RNAs (piRNAs), transcription
initiation RNAs (tiRNAs), small nucleolar RNAs (snoRNAs),
promoter-associated small RNAs (PASRs), promoter upstream
transcripts (PROMPTs), and TSS (transcriptional start site)-
associated RNAs (TSSa-RNAs). On the other hand, long ncRNAs
(lncRNAs) group heterogeneous non-coding transcripts such as
intergenic non-coding RNAs (lincRNAs), ultraconserved regions
(T-UCRs) and other ncRNAs collectively named lncRNAs (17,
19). miRNAs have been the most widely studied class of
ncRNAs in tumor biology. Since its discovery two and a
half decades ago, many miRNAs have been implicated in the
development of multiple human cancers through a wide range
of mechanisms. Among all these mechanism, gene silencing has
been predominant (20, 21). Mirroring what we have learned
about cancer-associated coding genes, we can classify miRNAs
into oncogenic or tumor suppressor (22). Moreover, miRNAs
have become actionable targets for cancer treatment and several
therapeutic agents are under development including some that
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TABLE 2 | Survival rates for colorectal and gastric cancer.
Stage Colorectal Stage Stomach
Colon Rectum
0 – – 0 –
I 92 87 IA 92
IIA 87 80 IB 87
IIB 63 49 II 63
IIIA 89 84 IIIA 89
IIIB 69 71 IIIB 69
IIIC 53 58
IV 11 12 IV 53
Five-year survival rates (%) for colorectal and gastric cancer patients are shown according
to the tumor staging system. Stage 0: Abnormal cells are found but confined in the tissue
of origin; Stage I: Tumor cells are found but confined in the tissue of origin; Stage II:
Tumor cells have spread deeper into the gastrointestinal wall; Stage III: Tumor cells have
spread into nearby lymph nodes; Stage IV: Tumor cells have spread to distant tissues and
organs. Data was extracted from ESMO Clinical Practice Guidelines (European Society
for Medical Oncology) (12–15).
have reached clinical trials (23–25). Currently, there is a growing
interest in lncRNAs biology and their role in the tumorigenic
process. These transcripts are generated by RNA polymerase
II, can be capped, spliced and polyadenylated, but lack an
obvious open reading frame. According to the latest release of
the GENCODE project (GRCh38.p12), which aims to build an
encyclopedia of genes and gene variants, the human genome
contains 16,066 lncRNA genes encoding for 29,566 different
lncRNA transcripts (26–29). This number represents 27% of all
annotated human genes.
Next-generation sequencing of large numbers of tumor
specimens has revealed thousands of lncRNAs aberrantly
expressed in a broad spectrum of cancers (30, 31). Dysregulation
of certain lncRNAs leads to the hyper- or hypoactivation of
cellular pathways that promote and/or sustain tumor initiation
and progression (32). LncRNAs are involved in a broad range
of processes such as transcriptional regulation of neighboring
protein-coding genes, interference of miRNAs via sequence
complementary, protein decoy, protein stability control, post-
transcriptional processing, epigenetic regulation, high-order
chromosomal dynamics, telomere biology, and subcellular
structural organization (32–35). LncRNAs mediate all these
functions through the interaction with proteins, RNAs and
lipids. It is remarkable that unlike other ncRNAs, the function
of lncRNAs cannot be inferred from sequence or structure
and thus, experimental evaluation needs to be conducted for
a full and accurate biological annotation (30). Because of their
undeniable role in cancer biology, the therapeutic targeting
of oncogenic lncRNAs and lncRNAs involved in resistance to
treatment has raised significant attention. The main strategies
to inactivate oncogenic lnRNAs aim their post-transcriptional
degradation with siRNAs, or the steric blockade of lncRNA-
protein interactions with small molecules, morpholinos, or
antisense oligonucleotides (36, 37). Noteworthy, some intrinsic
features of lncRNAs make them very attractive as cancer
diagnostic and prognostic biomarkers (38). First, lncRNAs
are expressed in a more tissue-specific manner than protein-
coding genes. It has been estimated that 78% of all lncRNAs
are tissue-specific, while protein-coding genes barely reach
19% of specificity (39). Additionally, lncRNAs dysregulation
in primary tumors and metastasis is observed in body fluids,
i.e., whole blood, plasma, urine, saliva, and gastric juice
(40). And despite the high abundance of ribonucleases in
most of these fluids, lncRNAs are easily detected due to its
high stability. This represents a clear advantage to patients
as it allows cancer diagnosis and follow-up using minimally
invasive methodologies.
Cancer cells show a plethora of chromosomal abnormalities,
including translocations, amplifications, and deletions. The
plasmacytoma variant translocation 1 (PVT1) gene encodes
a lncRNA that was first identified when studying a recurrent
translocation breakpoint in the Igκ locus found in murine
plamacytomas (41). One year later, a homologous human
sequence was identified when studying immunoglobulin
translocations in Burkitt lymphoma (42). We now know
that PVT1 gene fusions occur in additional hematologic
malignancies, such as non-Hodgkin lymphoma and advanced
multiple myeloma (10, 43, 44). PVT1 gene fusions are also
found in solid tumors although at much lower rates (10, 43, 44).
PVT1 exon 1 and intron 1 are most often involved in these
DNA rearrangements (45). In addition, human PVT1 is a
target of genetic gains and amplifications in a large variety of
cancers, including those of the digestive tract (46, 47). Moreover,
genome-wide association studies (GWAS) identified single
nucleotide polymorphisms (SNPs) in the PVT1 locus (8q24)
that are associated with increased colorectal cancer risk (48). Of
interest, PVT1 locus leads to the production of a cluster of four
annotated miRNAs, namely miR-1204, miR-1205, miR-1206,
and miR-1207 (-5p and -3p), being some of them important in
the tumorigenic process of colorectal and gastric cancer (49–52).
It is of note that although PVT1 has been mostly studied in the
context of cancer, this lncRNA is related to multiple and diverse
pathologies (Table 3).
In this review, we will discuss the current knowledge of
PVT1 alteration/dysregulation, as well as its contribution to
gastrointestinal cancer.
PVT1 EXPRESSION IN NORMAL AND
TUMOR TISSUE
Most lncRNAs exhibit a great number of isoforms and PVT1
is not an exception (53). Human PVT1 locus resides in
chromosome 8q24.21 and contains 21 exons leading to 25
annotated transcript variants (54). These variants arise as
a consequence of alternative splicing mechanisms mediating
exon skipping and the use of unconventional donor and
acceptor splice sites. Thanks to consortia such as The
Genotype-Tissue Expression Project (GTEx) and The Cancer
Genome Atlas (TCGA), we know that among all these PVT1
transcripts, 14 are present in tissues at detectable levels (7,
55–58). Specifically, 11 PVT1 transcripts have been detected
in the normal gastrointestinal mucosa and adenocarcinomas
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of the colon and stomach (Figure 1). Among them, PVT1-
217 (ENST00000523190) containing only four exons, is the
most abundant PVT1 transcript in the digestive tract. This
heterogeneity in isoform expression needs to be considered
when studying the role of PVT1 in carcinogenesis, as the
biology of each isoform might have a different impact on tumor
initiation/progression and patient survival. Several oncogenic
mechanisms have been attributed to PVT1, i.e., as a ceRNA
(competing endogenous RNA) for several miRNAs and as a
source of miRNAs itself (49, 51, 59–65). As a non-coding
gene, all of them rely into PVT1 RNA primary and secondary
structure. Accordingly, the biological activity of PVT1 depends
on the sequence of the specific PVT1 transcripts expressed
in a given tissue at a given time. Unfortunately, very few
reports have taken into consideration the large heterogeneity
in PVT1 isoform expression and consequently, some of the
results described in this review require further investigation.
Nonetheless, multiple studies assessing PVT1 expression by
means of microarray technology (66–68) or RT-PCR using
oligonucleotides amplifying several PVT1 isoforms, have shown
a general overexpression of PVT1 in colorectal tumors compared
to paired normal tissue samples (66, 68–74). Only He et al. have
examined the expression of individual PVT1 splice variants (Sv)
in colorectal cancer (68). They found PVT1 Sv-214, Sv-205, Sv-
209, Sv-208, Sv-206, Sv-207, Sv-213, Sv-219, Sv-201, and Sv-215
upregulated in colorectal cancer vs. normal samples (variants
ranked by decreasing overexpression fold) (68). Similarly,
increased PVT1 expression has been described in primary gastric
tumors compared to the normal gastric mucosa (75–78). PVT1
isoform Sv-214 overexpression was found in primary gastric
tumor samples compared to adjacent normal gastric tissue
(79). In good agreement, increased PVT1 expression in COAD
(colorectal adenocarcinoma), READ (rectal adenocarcinoma)
and STAD (stomach adenocarcinoma) samples compared to the
corresponding normal tissue was revealed using transcriptomic
expression data available at the TCGA repository (57, 80).
Interestingly, the tumorigenic process does not seem to affect the
relative abundance of PVT1 isoforms (Figure 1), being PVT1 Sv-
217 the isoform also more abundant in tumors. Unfortunately,
the studies investigating the expression and role of PVT1 in
gastrointestinal malignancies have not addressed directly or
indirectly the expression of this isoform (66, 68–72, 75–78). All
these observations have been extended to human cancer cell lines.
Precisely, CACO2, SW480, SW620, HT29, and HCT116 cells
derived from human colorectal tumors displayed higher levels of
total PVT1 compared to NCM460, FHC and HCoEpiC normal
colonic epithelial cells (67, 70, 72, 81). Likewise, AGS, MKN45,
SGC7901, and BGC823 gastric cancer cell lines have higher PVT1
expression compared to GES1 normal gastric epithelium cell line
(76, 79).
PVT1 expression in stomach cancer is directly regulated by
FOXM1 (Forkhead Box M1) transcription factor (75). FOXM1
controls the expression of genes such as MYC, CCNB1, AURKB,
and SKP2, which are essential for cell cycle progression at
DNA replication and mitosis, and therefore important for tumor
initiation and progression (82–85). Additionally, FOXM1 plays a
key role in DNA damage checkpoint participating in the repair
of DNA strand breaks (86). PVT1 transcript levels changes upon
manipulation of FOXM1 protein expression in gastric cancer
cells. Specifically, PVT1 expression is reduced upon FOXM1
silencing and increases after FOXM1 overexpression (75). This
regulation occurs through a direct interaction of FOXM1
with two independent binding sites in the PVT1 promoter
that enhances the transcriptional activation of this lncRNA
(75). In addition, STAT3 (Signal Transducer and Activator of
Transcription 3) has also been shown to regulate the expression
of PVT1 (77). Persistent STAT3 activation in tumor cells results
in increased cell proliferation, survival, and invasion; and at
the same time, STAT3 exerts non-cell autonomous effects in
the tumor microenvironment by boosting tumor-promoting
inflammation and suppressing anti-tumor immunity (87). STAT3
overexpression in gastric cancer cell lines leads to increased PVT1
levels, while STAT3 knockdown results in PVT1 transcriptional
downregulation. These effects are explained by the presence
of three canonical STAT3 binding motifs within the PVT1
promoter, which were confirmed to control the transcription of
this lncRNA (77) (Figure 2).
In colorectal cancer, PVT1 transcription is influenced by p53
(50). This tumor suppressor is involved in the cell cycle regulation
by transactivating a plethora of protein-coding but also non-
protein-coding genes, that ultimately prevent cell division by
inducing cell cycle arrest, senescence, or apoptosis (88, 89).
Importantly, p53 is the most frequently mutated gene in human
cancers (90, 91). The promoter of PVT1 harbors a functional
p53 response element that enhances the transcription of this
lncRNA in colorectal cancer cell lines exposed to the DNA
damaging agent daunorubicin, or upon increased p53 protein
levels achieved by the use of Nutlin-3a (50). It is important
to mention that PVT1 upregulation upon these conditions was
only monitored in p53 wild-type colorectal cancer cell lines and
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FIGURE 1 | Expression of PVT1 isoforms in normal and tumor tissue from the gastrointestinal tract. Eleven of the twenty-five predicted PVT1 isoforms are expressed
in the gastrointestinal tract. Transcripts variants are ranked from top to bottom according to their expression abundance (%) both in colon and stomach. Purple
histograms illustrate the expression in normal tissue samples from GTEX database (colon n = 204 and stomach n = 204). Blue histograms illustrate the expression in
tumor tissue samples from TCGA repository (colon adenocarcinoma n = 723 and stomach adenocarcinoma n = 453). Exon display for each PVT1 transcript variant is
shown. Data was extracted using UCSC Xena Browser.
thus, it remains unknown the ability of mutant p53 proteins to
exert an equivalent role. Although most p53 mutations result
in expression of dominant-negative forms, certain mutations are
known to confer oncogenic functions (92) (Figure 2).
PVT1 AND MYC
High-resolution analyses of somatic copy-number alterations
indicate that 8q24.21 region is one of the most frequently
amplified regions across human cancers, including colorectal
and gastric cancer, and are often associated with poor prognosis
and/or drug resistance (7, 58, 93). Interestingly, although the
amplified region spans almost 2Mb the only protein coding gene
in this locus is the MYC oncogene. This fact led to nickname
this region as the gene “dessert” locus, and attribute to MYC
the tumor promoting effects of gaining supernumerary copies of
8q24 (66, 94–96). Conversely, 8q24.21 has been shown to be an
“oasis” for lncRNAs. Up to 12 lncRNAs have been identified in
this locus, and very importantly for colorectal cancer, many of
them regulate Wnt signaling pathway and in turn Myc activity
(35, 69) (Figure 2). Wnt signaling is crucial for the initiation and
maintenance of colorectal cancer and consistently, this pathway
is altered in more than 90% of these malignancies according to
the TCGA data (58). Wnt dysregulation in gastric tumorigenesis
is less frequent but affects 10–30% tumors (7, 97). Accordingly,
PVT1 and MYC coamplification (66, 78, 98) and coexpression
(71, 98, 99) has been observed in colorectal and gastric primary
tumors and cell lines (Figure 3).
The first evidence of PVT1 in human solid malignancies,
and also its relationship with MYC, came from the study of
COLO320, a colorectal cancer cell line that was known to be
MYC amplified. Two variants of the cell line were isolated:
COLO320-HSR (homogeneous stained region) with MYC allele
intrachromosomically amplified; and COLO320-DM, with a
rearranged and amplified MYC allele that is carried on small
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FIGURE 2 | Chromosome 8q24.21 amplification and PVT1 gene structure and regulation. 8q24.21 chromosomal region is frequently amplified in colorectal and
gastric cancers (upper). This region contains MYC as the only protein-coding gene (yellow boxes) and several lncRNAs. Those lncRNA involved in MYC or WNT
regulation have been depicted (blue and black boxes) (middle). PVT1 lncRNA expression is regulated by FOXM1, STAT3, and p53 transcription factors. PVT1
promoter exhibits four enhancer regions that in normal conditions (WT) boost its own expression. Due to PVT1 promoter mutations and rearrangements (MUT), which
are frequently found in cancers, enhancer elements preferentially interact with MYC promoter enhancing the transcription of the oncogene. PVT1 encodes for four
miRNAs. miR-1204 has been show to stabilize p53 protein, while miR-1207 has been proven to modulate TERT protein at the post-transcriptional level and
expression of stemness and EMT genes by mechanisms currently unknown (lower). Pictograms in purple and green illustrate evidences obtained in colorectal and
gastric cancer, respectively. Dark gray boxes indicate gene promoters. Dark blue boxes indicate enhancer regions. Green and red arrows indicate up- and
down-regulation, respectively.
fragments of extrachromosomal DNA named double minutes
(100). By studying MYC amplification in COLO320-DM, the
authors noticed that intron 1 from MYC contained an ectopic
DNA fragment which they characterized and described as PVT1
in humans (101). However, the architecture of the MYC-PVT1
locus in COLO320-DM was later realized to be unique, since
PTV1 locus normally lies 57 kb downstream of MYC gene.
This chromosomal organization is conserved in other species
such as mouse and rat, with syntenic 15qD1 and 7q33 regions,
respectively (99).
The expression of PVT1 and MYC in tumors are correlated
not only because of their genetic coamplification. The 8q24
region displays a very strong enhancer activity creating feedback
loops controlling MYC expression (102). Precisely, lncRNAs
within 8q24 region are efficiently transcribed due to the
presence of abundant transcriptional factors and mediator
proteins, and these lncRNAs in turn, increase the enhancer
activity by forming chromatin loops and protein bridges to
promote the transcription of MYC (71, 98, 103). Interestingly,
PVT1 promoter is recurrently rearranged in human tumors,
including those affecting the digestive tract (10, 44, 104).
It has been demonstrated experimentally that insertions or
deletions in the PVT1 promoter lead to Myc overexpression and
consequently, enhanced growth in cancer cells (104). Chromatin
is organized into self-interacting units called topologically
associating domains (TADs). Contacts between promoter and
enhancer regions take place within the TADs, leading to an
additional layer of gene expression regulation (105). As a
consequence, genomic DNA structural variations, i.e., deletions,
duplications, insertions, inversions, and translocations, are
able to modify the three-dimensional chromatin topology and
promote or suppress promoter-enhancer interactions within
the TADs (104, 106). PVT1 gene harbors four intragenic
enhancer elements that under normal conditions establish strong
interactions with the PVT1 promoter and sustain expression of
the non-coding transcript. However, under the PVT1 promoter
mutational rearrangements found in tumor cells, and even
epigenetic inactivation, PVT1 intragenic enhancer elements
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FIGURE 3 | PVT1 and MYC expression in gastrointestinal tumors and cell lines. PVT1 and MYC copy number variation (A,B) and RNAseq expression (C,D) in tumor
samples from colorectal (n = 616) and stomach (n = 441) adenocarcinomas (A,C) and established cell lines from colorectal (n = 58) and gastric tumors (n = 38)
(B,D). The name of cell lines used in studies investigating the role of PVT1 in gastrointestinal cancer are shown. Gray boxes indicate no alteration. Light blue boxes
indicate gene amplification. Dark blue boxes indicate gene deletion. RNAseq expression units: RPKM (Reads Per Kilobase Million). Pearson and Spearman correlation
coefficients and associated p-value (Spearman) are shown.
interact preferentially with MYC promoter, thus boosting the
transcription of MYC oncogene and its oncogenic activity of
tumor cells (104) (Figure 2).
ONCOGENIC PVT1 FUNCTIONS IN
COLORECTAL AND GASTRIC CANCER
LncRNAs carry out their biological functions through multiple
and diverse mechanisms. Several research groups have
demonstrated the overall ability of PVT1 to sustain in vitro
and in vivo cell growth, clonogenicity, migration, and invasion,
both in colorectal (66–68, 71, 72, 107) and gastric cancer
epithelial cells (75–77, 79). The capacity of PVT1 to negatively
regulate apoptosis through the inhibition of the TGFβ pathway,
is more controversial, as it has not been observed systematically
(66, 70–72, 78, 79, 107, 108). PVT1 lncRNA has been shown to
exert its protumorigenic activity also in a non-cell autonomous
manner. Precisely, PVT1 expression in gastric tumors enhances
microvessel formation, both in vitro and in vivo, through a
mechanism that involves vascular endothelial growth factor
A (VEGFA) expression in a STAT3-dependent manner (77).
Formation of new vessels is a crucial step for tumors to maintain
the supply of oxygen and nutrients, and VEGFA is a master
regulator of this process (109). Consistently, antiangiogenic
agents are routinely used in the clinical practice to treat cancer
patients (110, 111). Antiangiogenics are used in combination
with chemotherapy in the first line of treatment of colorectal
cancer, and several compounds targeting tumor vasculature
have been recently approved for the management of gastric
cancer (13, 14, 112). In fact, expression of PVT1 and VEGFA
in combination predicts poor survival in gastric cancer, further
supporting the use of antiangiogenic drugs in these patients (77).
All these results have been obtained upon genetic
manipulation of PVT1 levels in cell line models, and it is
important to mention that these manipulations have not been
restricted to a single PVT1 isoform (68). The siRNAs often used
to achieve downregulation of PVT1 target multiple transcripts,
and not always those predominantly expressed in colorectal
and gastric tumors. On the other hand, models of PVT1
overexpression do not adequately report the specific isoforms
used. The only exception is the study of He et al., where they
convincingly demonstrated in HCT116 and SW480 colon cancer
cell lines, the ability of PVT1 Sv-214 to promote proliferation,
stemness, migration and invasion in vitro; as well as in vivo by
establishing tumor xenografts and liver metastasis mouse models
in immunodeficient nude mice (68). Importantly, differences
in the PVT1 isoforms downregulated in different studies might
explain the discrepancies reported regarding the role of PVT1
to regulate apoptosis. In this line, the suitability of certain
PVT1 knockdown cellular models exhibiting apoptosis to assess
invasion and/or migration properties should be reconsidered.
miRNA Production
PVT1 locus leads to the production of a cluster of four annotated
miRNAs, namely miR-1204, miR-1205, miR-1206, and miR-1207
(-5p and -3p) (49, 51) (Figure 2). Originally, miR-1208 was
also mapped into PVT1 locus, but according to latest version
of Ensemble Genome browser (v98) this miRNA lies outside
the lncRNA sequence (54). All these miRNAs are conserved
in the mouse Pvt1 gene (51). As depicted in Figure 4, most
of the miRNAs contained within the PVT1 transcript variants
expressed in the colon and stomach are found in intronic
regions. Spatiotemporal organization of the RNA splicing has
important implications to fully understand the PVT1 loss-of-
expression experiments found in the literature (113). Gene
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FIGURE 4 | miRNAs encoded by PVT1 transcript variants. PTV1 isoforms are ranked according to expression abundance (%) in gastrointestinal normal tissues and
tumors. Gray and blue boxes indicate absence and presence of the indicated miRNA, respectively. Nucleotide sequence, length, and location within PVT1 introns or
exons is indicated for all miRNAs.
silencing using exogenous siRNA against exonic regions does
not necessary entail that the miRNAs encoded within introns
will also be silenced. Upon splicing in the nucleus, introns are
available for microRNA processing while the spliced transcript
is exported to the cytoplasm where it may be targeted by
exogenous siRNAs. This might explain why the use of siRNAs
against PVT1 in HCT116 and RKO cells did not have any
effect on the expression of miR-1204, miR-1205, and miR-1207-
5p/3p (66). Contrary, expression of all PVT1-encoded miRNAs
was enhanced upon exposure of the cells lines to the DNA
damaging agent daunorubicin, or upon increased p53 protein
levels achieved through Nutlin-3a stimulation (50). This, effect is
likely to be indirect because, as mentioned before, PVT1 increases
as consequence of p53 stabilization. Among the four PVT1-
encoded miRNAs, only miR-1204 seems to engage a positive
feedback loop to sustain stabilization of p53 at protein level (50).
The role of PVT1-encoded miRNAs in the initiation and/or
progression of malignancies in the stomach or colon is uncertain
due to the lack of literature. Only miR-1207 is reported to
have an effect in gastric cancer proliferation and invasion,
or in the stemness properties of colon cancer cells (52, 81).
Specifically, it has been shown how ectopic expression of miR-
1207-5p in the SGC7901 gastric tumor cell line is able to reduce
proliferation and invasion in vitro and in vivo by targeting
the catalytic subunit of the telomerase complex hTERT (52).
Aberrant expression of hTERT is associated with the metastatic
ability of gastric tumors (114, 115). In turn, miR-1207-5p
overexpression in the HCoEpiC normal colon epithelial cell line
enables the formation of primary and secondary spheres by a
mechanism involving the upregulation at the mRNA level of
TGFβ, CTNNB1, MMP2 and several colorectal stem cell markers
such as CD44, CD133, and CD166 (81). Consistent with the
tight relationship between stemness and epithelial-mesenchymal
transition (EMT), Slug, Snail, and vimentin were also found
upregulated (81, 116) (Figure 2). Interestingly, miR-1207-5p
miRNA seems to exhibit oncogenic activity in colorectal cancer
while having tumor suppressor effects in gastric cancer cells
(contrary to the oncogenic role of PVT1).
ceRNA
LncRNAs have the ability to modulate gene expression indirectly
by impairing miRNA activity through sequestration/sponging,
which leads to an effective de-repression of targets of these
miRNAs (33, 34). This function, named competitive endogenous
RNA (ceRNA), has encountered certain skepticism due to the
fact that the physiological expression levels of an individual
lncRNA may not be sufficient to completely suppress the activity
of miRNAs (117). However, regulation by modestly expressed
lncRNAs could be magnified through downstream processes,
particularly through the upregulation of transcription factors
that by transactivating multiple targets contribute to outcome
amplification. This might be the case for PVT1, which as shown
here maintains a close relationship with Myc, p53 and STAT3, all
of them key transcription factors in the tumorigenic process.
miR-152
miR-152 suppresses the proliferation and motility of gastric
cancer cells targeting CD151 and FGF2, which are cell
surface receptors well-known to participate in the spreading,
migration and invasion of tumors (118–120) (Figure 5). miR-
152 expression is downregulated in gastric cancer tissues, most
likely as a result of the interaction with PVT1 which has been
shown in vitro to effectively sponge this miRNA (60, 118).
In good agreement, PVT1 is negatively correlated with miR-
152 expression in tumors from gastric cancer patients, and
its genetic manipulation in SGC7901 and BGC823 gastric cell
lines influences miR-152 levels and ultimately, CD151 and FGF2
expression (60). It is noteworthy that three independent binding
sites for miR-152 have been identified in PVT1, however not all of
them are present in the transcripts more frequently expressed in
the gastric tissue (Figure 6). No reports are found in the literature
regarding the role of PVT1 in sponging miR-152 in colorectal
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FIGURE 5 | PVT1 interaction with miRNAs and proteins. PVT1 interacts with multiple miRNAs and proteins in cancer cells, leading to post-transcriptional (1) and
post-translational (2) regulation of gene expression. PVT1-miRNA interactions promote efficient de-repression of miRNA targets. Specifically, PVT1 hinders miRNAs
binding in the 3′ untranslated region of target transcripts, preventing their degradation by the RISC complex and thus increasing protein levels. PVT1-protein
interactions stabilize proteins and prevent their degradation. Pictograms in purple and green illustrate PVT1-miRNAs/proteins interactions identified in colorectal and
gastric cancer, respectively.
tumors. However, as observed for gastric tumorigenesis, this
miRNA acts as a tumor suppressor in colorectal cancer cell lines
and its expression is downregulated in primary colorectal tumors
(121, 122).
miR-186
This tumor suppressor miRNA negatively regulates the
proliferation, invasion and migration of gastric cancer cells by
impairing the EMT process through TWIST1 targeting and
degradation (123). miR-186 regulates the expression of hypoxia
inducible factor 1α (HIF-1α) and blocks aerobic glycolysis in
gastric cancer cell lines (124). HIF-1α is a key protein regulating
the response of cells to low levels of oxygen (125). In cancer, HIF-
1α is significantly associated with metastasis, stemness and poor
prognosis and thus, tumors engage sophisticated mechanisms
to keep its expression at high levels (126). Gastric cancer cell
lines with PVT1 overexpression show increased HIF-1α mRNA
and protein levels, that are reduced with a miR-186 mimic.
Conversely, the decreased HIF-1α levels achieved by PVT1
downregulation are rescued upon usage of a miR-186 inhibitor
(124) (Figure 5). PVT1 binding to miR-186 occurs through a
single interacting site, which according to in silico analysis is
present exclusively in PVT1-Sv203 (Figure 6). miR-186 role in
colorectal cancer pathogenesis is not so clear. Some reports have
identified miR-186 [5p] as a tumor suppressor due to its ability
to inhibit proliferation, metastasis and EMT of colorectal cancer
cells by targeting ZEB1, while others point out in the opposite
direction (127–129).
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FIGURE 6 | Predicted sponge capacity of miRNAs by PVT1 transcript variants. PTV1 isoforms are ranked according to their relative expression abundance (%) in
gastrointestinal normal tissues and tumors. Gray and solid blue boxes indicate absence and presence of the nucleotide sequence complementary to the different
miRNA, respectively. Patterned blue boxes indicate complementarity with miR-128 principal binding motif, but lack of the additional contact sites and/or difference in
length from the main interacting core. Nucleotide sequence of the miRNA binding site is specified.
miR-455
PVT1 acts as a ceRNA to negatively regulate the expression of
miR-455 in HT29 and SW480 colon cancer cell lines (72). Hsa-
miR-455 encodes for two miRNAs: miR-455-5p and miR-455-3p.
PVT1 seems to specifically bind to miR-455-5p (Figure 6). This
miRNA is frequently downregulated in colorectal tumors and
acts predominantly as a tumor suppressor element by targeting
phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1) and
Runt-related transcription factor 2 (RUNX2), both crucial for the
development of tumors (72, 130, 131) (Figure 5). An equivalent
tumor suppressor role has been attributed to miR-455 in gastric
tumorigenesis (132, 133).
miR-128
In silico analysis identified PVT1 Sv-214 as ceRNA for miR-
128, and the initial observation was confirmed experimentally
in colorectal cancer cell lines through gain and loss-of-function
experiments against PVT1 Sv-214 isoform and further extended
to gastric cancer cell line model (68, 79). Moreover, the
expression of miR-128 showed a significant inverse correlation
with the expression of PVT1 Sv-214 in colorectal and gastric
primary tumor samples. As depicted in Figure 6, the central
interacting motif between PVT1 Sv-214 and miR-128 is present
in several transcript variants. However, the additional contact
sites between the lncRNA and the miRNA pointed out by
the authors are not always present in these variants or
alternatively differ in length from the central motif. Therefore,
the capacity of these PVT1 isoforms to sponge miR-128 should be
confirmed experimentally. miR-128 targets the Lin28 transcript
for degradation in colorectal cancer cell lines (68). Lin28 is an
RNA-binding protein that inhibits the processing of let-7 family
of miRNAs. Let-7 regulates the translation of mRNAs important
for the embryo development, cell pluripotency, metabolism, and
tumor progression (68, 134). In line with this observation, the
expression of PTV1 Sv-214 and let7a negatively correlated in
colorectal cancer patient samples (Figure 5). Notably, Lin28
cooperates with Wnt signaling and Snail to drive growth and
invasiveness in colorectal and gastric tumors, respectively (135–
137). Conversely, in gastric cancer cell line systems, miR-128
was shown to target TrkC (79) (Figure 5). TrkC/NTRK3 is a
member of the NTRK neurotrophin tyrosine kinase receptor
family and functions as a tumor suppressor. TrkC is considered
a dependence receptor, which is characterized by its ability to
induce opposing biological effects depending on the availability
of the ligand, NT-3. In the presence of the TrkC ligand, a survival
signal is transduced, whereas its absence results in cleavage of a
death-domain peptide and induction of apoptosis. NT-3 levels
are reduced in CRC and consistently with the tumor suppressor
activity of the receptor, tumors tend to accumulate inactivating
point mutations or silence protein expression by means of
promoter methylation (138, 139). Interestingly, gastric tumors
seem to achieve TrkC inactivation through miR128-mediated
transcript degradation.
miR-214
Bioinformatics analysis also allowed the identification of PVT1
as a sponge for miR-214-3p. This miRNA negatively regulates
the expression of IRS1 (Insulin receptor substrate 1) in the colon
cancer cell line HCT116 (107). IRS1 is a key signaling mediator
of the insulin/insulin-like growth factor (IGF) system controlling
Frontiers in Oncology | www.frontiersin.org 10 January 2020 | Volume 10 | Article 38
Martínez-Barriocanal et al. PVT1 in Gastrointestinal Cancer
cellular proliferation, differentiation, EMT, and apoptosis in
colorectal cancer (140, 141). Upon phosphorylation by the
insulin receptor, IRS1 binds specifically to cellular proteins
containing SH2 domains such as phosphatidylinositol 3-kinase
(PI3K) regulatory subunit (p85) or GRB2, leading to activation
of PI3K and MAPK signaling pathways, respectively (142, 143)
(Figure 5). Accordingly, both PVT1 and miR-214-3p sustained
the expression and activation of PI3K catalytic subunit (p110)
and Akt in colon cancer cell line models (107). No reports have
described so far PVT1 binding to miR-214 in gastric cancer.
However, this might not contribute for stomach carcinogenesis,
as miR-214 displays an oncogenic role rather than tumor
suppressor in gastric epithelial tumor cells. Specifically, miR-214
was been found upregulated in gastric tumors and sustains cell
proliferation, migration and invasion by targeting GSK3β, PTEN,
PRDM16, and A2AR (144, 145).
Protein Stabilization
LncRNA can also interact with proteins and regulate their
stability by preventing post-translational modifications
associated with protein degradation. Specifically, PVT1 has
been shown to bind and stabilize some proteins that are relevant
in the gastrointestinal tumorigenesis, such as STAT3 and Lin28.
STAT3
PVT1 has been shown to interact with transcription factor STAT3
in gastric cancer cell lines. Binding of PVT1 to STAT3 restricted
STAT3 ubiquitin-proteasomal degradation leading to sustained
phosphorylation and nuclear translocation of the transcription
factor (77) (Figure 5). As described before, STAT3 has a strong
role supporting tumor progression and therefore, significant
efforts have been aimed at the development of specific and
non-toxic inhibitors for cancer treatment (146, 147).
LIN28
RNA immunoprecipitation followed by mass spectrometry
identified Lin28 as a protein interacting directly with PVT1
Sv-214 (68). Lin28-PVT1 complex formation prevented Lin28
degradation by the proteasome, increasing the steady-state levels
of this RNA-binding protein. Consistently, Lin28 protein levels
were reduced in vitro and in vivo when PVT1 was knocked
down using siRNAs technology, and increased when PVT1 was
overexpressed (Figure 5). The interaction between Lin28 and
PVT1 is known to take place in the cytoplasm and to involve
the 3′ region of PVT1 Sv-214. Although the specific binding
site has not been mapped, it is known to be contained within
nucleotides ranging from position 672 and 922 in this PVT1
isoform and encoded by a small portion of exon 17 and full
exons 18 and 19. Therefore, besides PVT1 Sv-214, only PVT1
Sv-217 could potentially interact with Lin28. Altogether, Lin28
is regulated by PVT1 through two independent mechanisms:
(1) post-transcriptionally, preventing Lin28 transcript targeting
by mir-128, as described above, and; (2) post-translationally,
reducing Lin28 protein degradation by the proteasome
machinery (68).
FIGURE 7 | Epigenetic regulation by PVT1. PVT1 recruits EZH2 polycomb
group protein leading to promoter methylation and transcriptional repression of
CDKN2A (p16) and CDKN2B (p15).
Epigenetic Regulation
LncRNAs are important epigenetic regulators and in turn,
perturbations of epigenetic regulation are thought to be a key
feature of many cancers and even driver events (148). Twenty
percent of all human lncRNAs have been shown to physically
associate with Polycomb Repressive Complex 2 (PRC2 complex),
which operates as a transcriptional repressor (149, 150). PVT1
has been shown to recruit Enhancer of Zeste homolog 2
(EZH2) to epigenetically negatively regulate the expression of
p15 and p16 in gastric cancer cell lines (78). Interestingly, in
primary gastric tumors PVT1 correlates positively with EZH2
and negatively with p15/p16 protein levels (78) (Figure 7).
PVT1 AS A PROGNOSTIC BIOMARKER
PVT1 is clearly dysregulated in gastric and colorectal cancer,
and experimental mechanistic studies convincingly demonstrate
that elevated levels of this lncRNA promote proliferation,
angiogenesis and metastasis in human malignancies.
Consistently, possible associations between PVT1 levels and
patient prognosis have been investigated by several independent
groups. However, as mentioned before, PVT1 exhibits a
significant variability in transcript expression and this has not
been rigorously considered when interrogating PVT1 levels in
primary tumors. Most of the studies have determined PVT1
expression by means of qPCR-based techniques, and surprisingly
none of them directly assessed the expression of PVT1 Sv-217,
which according to datasets available in public repositories such
as TCGA, is the isoform predominantly expressed in colorectal
and stomach tumors (Figure 1) (151). Additionally, primers
targeting multiple isoforms have been used in most of the
studies, which might account for the differences observed in the
clinicopathological features correlating with PVT1 expression.
In colorectal cancer, the expression of PVT1 isoform Sv-214
was found to be positively associated with tumor size, advanced
stage (III-IV), distant metastasis, and reduced overall and
disease-free survival (70). PVT1 Sv-203 when amplified with
qPCR primers that could co-amplify Sv-202 and Sv-211 (66) (two
isoforms that according to genome-wide RNAseq profiling have
no detectable expression in colorectal malignancies) correlates
with advanced stage (III-IV), lymph node metastasis, venous
invasion, and decreased overall survival (66, 70). However, the
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expression of the same PVT1 isoform Sv-203, when determined
together with the expression of Sv-206 and Sv-212 (two isoforms
that are moderately expressed in colorectal tumors), was not
associated with the clinicopathological features described above
(69). Additional studies assessing PVT1 overall levels by means
of high-throughput technologies such as microarrays or RNA
sequencing, observed that high expression values were associated
with shorter patient overall survival (67, 152). Similarly, in
gastric cancer, elevated PVT1 expression was found to be
associated with high tumor stage (III–IV) (75–78), lymph node
metastasis (76) and overall/disease-free survival (78). PVT1 Sv-
214 specific evaluation in gastric cancer patients was associated
with larger tumor size (5 cm cut off), advanced stage (III-IV)
and reduced overall survival (79). Collectively, the available
literature supports the contention that elevated expression of
PVT1 is associated with poor prognosis of gastrointestinal
cancer patients, but additional isoform-specific studies
are warranted.
PVT1 AND RESISTANCE TO THERAPEUTIC
AGENTS
Current treatment for locally advanced colorectal and stomach
cancer involves surgical resection of the primary tumor
followed by adjuvant chemotherapy to lower the risk of
tumor recurrence. Certain patients are also eligible for
preoperative or neoadjuvant therapy, being radiation-based
treatment the best option for rectal cancer. Several drugs
are approved for the treatment of gastrointestinal cancer,
but nowadays ECF chemotherapy (epirubicin, cisplatin, and
5-fluorouracil) and FOLFOX/FOLFIRI/FOLFOXIRI regimens
(5-fluorouracil, leucovorin, oxaliplatin, and/or irinotecan)
constitute the standard of care for stomach and colorectal
cancer, respectively (12–15). Intrinsic and acquired resistance
to therapeutic agents is the first cause of treatment failure in
cancer patients (153). Therefore, identification of the molecular
pathways driving the resistance to chemotherapeutic drugs
and the screening of drug response biomarkers in cancer
patients is of paramount importance to maximize response
rates (154–156).
Several studies have investigated the expression of PVT1
in colorectal and gastric cancer patients treated with different
regimens. PVT1 was found upregulated using quantitative RT-
PCR in colorectal cancer patients refractory to 5-fluorouracil (5-
FU) in neoadyuvancy (primary resistance), and also in colorectal
and gastric cancer patients receiving but not benefiting from
cisplatin (70, 108, 157). These findings were consistent with
the results obtained using cellular models of acquired drug
resistance in vitro. HCT116 colon cancer cells resistant to the
combination of 5-FU and radiation displayed increased levels
of PVT1 compared to the parental cell line when evaluated
using a human lncRNA Expression Array (158). Assessment of
PVT1 transcript levels by quantitative RT-PCR in LOVO and
RKO colon cancer cell lines with acquired resistance to cisplatin,
or HCT8 and HCT116 with secondary resistance to 5-FU also
evidenced the transcriptional upregulation of PVT1 lncRNA
(70, 157). Likewise, BGC823 and SGC7901 gastric cancer cell
line models resistant to cisplatin exposure, exhibited increased
levels of PVT1 (108). Of note, all the cell lines used in these
studies were all MYC amplified, and in the case of the colorectal
cancer cell lines, also PVT1 amplified. It might have been very
interesting to investigate to what extent elevated PVT1 levels by
copy-number gain, are required for drug resistance. Interference
of PVT1 expression using siRNA technology in cisplatin resistant
cellular models resulted in a reduction of cell proliferation and
engagement of apoptosis (70, 108, 157). Mechanistically, some of
these effects could be attributed to MDR1 (Multidrug resistance
protein 1B) and MRP1 (Multidrug resistance-associated protein
1), which have been shown in vitro to modify their expression
at mRNA and protein level in a PTV1-dependent manner (70,
108, 157). Both proteins are plasma membrane efflux pumps
controlling the intracellular bioavailability of substrates at the
expense of ATP hydrolysis, and are well-known chemotherapy-
resistance mediators in cancer (159).
CONCLUSIONS AND FUTURE
PERSPECTIVES
PVT1 is an oncogenic lncRNA in many cancer types, including
colorectal and stomach cancer. This lncRNA is involved in
multifaceted aspects of cancer biology such tumor growth,
metastasis, and response to therapeutic agents through a complex
signaling network that involves interactions with DNA, RNA,
and proteins. PVT1 complexity starts at the transcriptional
level. Twenty-five splice variants have been described for PVT1
according the latest release of Ensembl database, being 11
of them detectable in colorectal and gastric normal/tumor
tissues with the current sequencing platforms. Surprisingly, this
complexity has been largely neglected when addressing PVT1
expression different in tissues. This is of special relevance if as
postulated by some authors, PVT1 is intended to be used as
a biomarker for diagnosis, personalized therapeutic treatment,
or even a new therapeutic target. Currently, there are no
reports associating PVT1 up-regulation with well-established and
clinically relevant molecular features of colorectal and gastric
tumors such as microsatellite stability (MSI/MSS), CpG island
methylator phenotype (CIMP+/CIMP−), consensus molecular
subtypes (CMS1, CMS2, CMS3, and CMS4 for colorectal cancer,
and MSI, EBV, CIN, GS for gastric cancer) or mutations in
key driver genes (APC, CTNNB1, SMAD4, TGFB1, TP53, KRAS,
PI3K, CDKN2A, CDH1, ERBB2, or RHOA).
Experimentally, more efforts should be invested in the
study of the primary, secondary, and higher-order structure
of PVT1 transcripts and PVT1 promoter region, which is
crucial for understanding the function of this lncRNA at a
molecular level. The role of PVT1 in colorectal and gastric
cancer has been addressed using gain-and-loss of function
experiments using gene overexpression and RNA interference
approaches in cell line systems, respectively. PVT1 encodes
multiple miRNAs in intronic regions. The nuclear localization
of spliced intronic sequences prevents optimal targeting by the
RNAi machinery, which is mainly localized to the cytoplasm.
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Alternative oligo-mediated RNA knockdown strategies, such
as modified antisense oligonucleotides or gapmers, should be
used to block PVT1 miRNA-mediated effects. Ideally, knock-
out/knock-in mouse models should be used to better assess the
role of PVT1 in cancer biology. However, compared to protein
coding genes, very few animal models have been generated to
assess the function of lncRNAs in vivo. Unfortunately, many
lncRNAs are not highly conserved hindering the identification
of mouse orthologs and full function evaluation still represents
a challenge.
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